Nosocomial Acinetobacter baumannii bloodstream infections occur with significant prevalence and mortality. The relationship between carbapenem resistance in A. baumannii and patient outcomes remains unclear. A retrospective cohort study was conducted on patients with A. baumannii bacteremia. Outcomes, controlling for confounders, were compared for carbapenem-nonresistant A. baumannii (CNRAB) and carbapenem-resistant A. baumannii (CRAB). The primary outcome studied was all-cause hospital mortality, and the secondary endpoints evaluated were time to mortality, time to negative cultures, and length of stay postinfection for survivors. A total of 79 patients, 37 infected with CRAB and 42 with CNRAB, were studied. Hospital mortality was greater in the CRAB group as determined based on bivariate analysis (P < 0.01); however, this effect was nullified when controlling for relevant confounders with logistic regression and a Cox proportional-hazards model (P ‫؍‬ 0.71 and 0.75, respectively). Values for time to mortality and time to negative cultures did not differ between the groups. The median number of days of stay postinfection for survivors was greater for the CRAB group than the CNRAB group (14 versus 6.5; P < 0.01). Patients who received active antimicrobial therapy were less likely to die (93.5% versus 74.2%; P ‫؍‬ 0.02), regardless of carbapenem susceptibility classifications, and this result was robust in the multivariate model (P ‫؍‬ 0.02). Trends existed for improved outcomes in patients receiving an active beta-lactam, and patients fared worse if they had received a polymyxin as an active agent. Patients with CRAB bloodstream infections were more chronically ill and had more comorbidities. Inactive therapy was more important than carbapenem susceptibility with respect to outcomes, was a strong predictor of death, and is potentially modifiable.
Nosocomial bloodstream infections are an important and prevalent cause of patient mortality. The attributable mortality rates for patients with Acinetobacter baumannii infections seen in a large multicenter study have been estimated as 34% in all patients and 43% in patients in intensive care units (ICUs), the third highest seen for any nosocomial bloodstream pathogen in each category (34) . Furthermore, antimicrobial resistance mechanisms are highly prevalent in A. baumannii as both constitutive resistance and acquired resistance (5) . Multidrug resistance and pan-resistance have become the rule rather than the exception with this pathogen, and multidrug resistance frequently requires a carbapenem as the treatment of choice. However, due to increasing exposure, carbapenem resistance rates have predictably risen, with strains of carbapenem-resistant A. baumannii (CRAB) reported worldwide (21, 25, 27) .
Recent studies have quantified mortality rates attributable to A. baumannii infection but have been unable to identify a definitive link between drug resistance and mortality (7) . In studies published to date assessing clinical outcomes of patients with bacteremia associated with carbapenem-resistant A. baumannii (8, 9, 14, 24) , none have analyzed outcomes according to specific treatment type or time to active therapy, and few have analyzed the more sensitive markers of morbidity such as length of stay. In this study we sought to compare differences in clinical outcomes for patients with A. baumannii bloodstream infections stratified by carbapenem resistance and type of antimicrobial therapy given.
(Portions of this research were presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 12 to 15 September 2009.)
MATERIALS AND METHODS
Study design and population. A retrospective cohort study was conducted at Northwestern Memorial Hospital (NMH) in Chicago, IL. Patients with at least one positive blood culture for A. baumannii identified between January 2005 and December 2008 were evaluated. Patients wiyh at least 18 years of age who received more than 48 h of treatment were included in the study. Patients with two or more positive blood cultures during the study period had only the first culture per individual patient included in the study. Cultures that had not been subjected to carbapenem (i.e., imipenem or meropenem) susceptibility testing were excluded if the isolate was not available from our frozen stores for testing. For carbapenem-resistant cultures, carbapenemase gene status was determined by PCR testing as previously described (23) . In brief, we analyzed isolates for the presence of bla , bla , bla OXA-58 , bla IMP , bla VIM , and bla SIM genes. This study was reviewed and approved by the Northwestern Memorial Hospital and Midwestern University Institutional Review Boards.
Organism identification and susceptibility classification. Species identification to the level of the Acinetobacter calcoaceticus-A. baumannii complex was completed using a Vitek II system (bioMérieux, Balmes-les-Grottes, France) and manual biochemical identification when necessary (29) . Antimicrobial susceptibility testing was performed on all isolates by the use of either the Vitek II system or Etest (AB bioMérieux, Solna, Sweden) to determine MICs. Organism susceptibility was interpreted according to Clinical and Laboratory Standards Institute (CLSI) guidelines (6) . Isolates were categorically classified as either carbapenem-resistant A. baumannii (CRAB) or carbapenem-nonresistant A. baumannii (CNRAB).
Molecular typing by PFGE. Pulsed-field gel electrophoresis (PFGE) was performed for all resistant isolates as previously described (23) , with the exception that digestion times of 90 min were used. The similarity between isolates was determined by visual comparison of the DNA banding patterns by using the criteria of Tenover et al. (33) , with isolates having 3 or fewer differing bands labeled as closely related, those with 4 to 6 differing bands considered possibly related, and those with more than 6 bands different considered genetically distinct.
Data collection. Patient demographics and data variables were collected using inpatient electronic medical records, pharmacy databases, and clinical microbiology databases. Recorded patient demographics included age, gender, absolute neutrophil count (ANC) of less than 500 cells/mm 3 , history of immunosuppression (i.e., corticosteroids or chemotherapy within the previous 6 months or HIV-positive status), hospital location (intensive care unit [ICU] versus non-ICU) at time of culture, duration of hospitalization prior to culture, receipt and duration (in days) of antibiotic administration prior to culture, and other patient comorbidities (diabetes, any transplant, kidney transplant, hepatic dysfunction, and renal dysfunction). The presence of a central line catheter at the time of culture was also noted. Hepatic dysfunction was defined as any liver function test value Ͼ3 times the upper limit of the normal value at the time of culture. Renal dysfunction was defined as the presence of documented chronic kidney disease, any form of dialysis, or an increase in serum creatinine level of 0.5 mg/dl or 50% at the time of culture from a previous value recorded at any time during the hospital stay (3, 4) . Clinical characteristics recorded related to bacteremia included whether A. baumannii was cultured from two or more sites and whether the bacteremia was polymicrobial. To differentiate complicated bacteremias, complex bacteremia was defined as bacteremia resulting from major organ infections, soft tissue infections, abscesses, or any necrotic infection (28) . Data elements collected to assess the quality of therapy included whether patients received active therapy, the number of days until active therapy, the class of active antibiotic, and the total number of antibiotic days postculture. Active therapy was defined as therapy with at least one antibiotic to which the A. baumannii strain was nonresistant as classified by the CLSI guidelines (6) . Specific doses were not reviewed; however, patients at Northwestern Memorial Hospital minimally receive doses concordant with national guidelines or doses of antibiotics appropriate for a more aggressive treatment (http://www.idsociety.org /Content.aspx?id ϭ 9088; accessed 7/5/11), with appropriate renal function adjustments. Administration of the correct therapy is ensured by utilization of standardized, prepopulated, computerized order sets and prospective clinical pharmacist participation in the care of each patient. Any deviations from this procedure that may be represented in this study sample were likely random.
Statistical analysis. The primary outcome studied was hospital mortality from any cause, and the secondary endpoints evaluated were days to mortality, days to negative cultures, and length of stay postinfection (in days) for survivors. Both the impact of active therapy and that of specific treatment were analyzed as modifying variables for the outcomes.
Data analysis was completed using Intercooled Stata version 10.1 software (StataCorp, College Station, TX). Bivariate analysis was conducted on all variables. Categorical data were analyzed using a chi square or Fisher's exact test where appropriate. Student's t test and the Wilcoxon rank-sum test were used for data that were normally distributed and data that were not normally distributed, respectively, for continuous variables. Differences between the two groups in rates of time to hospital mortality were compared using the Kaplan-Meier curve and the log-rank test for significance.
Multivariate analysis was conducted to assess the relationship between variables for all endpoints while controlling for confounders. Linear variables other than those that were normally distributed were log transformed. For the primary endpoint of hospital mortality, a stepwise logistic regression model was created using all predictor variables with a plausible relationship with the outcome and a P value Յ 0.20 for the bivariate level comparison. Additionally, variables commonly known to affect the dependent outcome were forced into the model (31) . Since carbapenem resistance status was a focal point in the study, it was determined a priori that it would be forced into the model. This calculation method is referred to here as model 1. To ultimately select the most parsimonious and explanatory model revealing differences between the treatment groups, a forward-selection technique was employed by assessing each variable iteratively added to the multivariate logistic model according to significance. Model selection was completed by determining values that represented twice the difference between the models in the log likelihood ratios and comparing the product to a chi square distribution with the appropriate degrees of freedom (i.e., 3.84 for 1 degree of freedom). This calculation method is referred to here as model 2. Similarly, confounders of the time-to-event analyses were assessed with a Cox proportional-hazards model. All tests were two-tailed tests, and P values of less than 0.05 were considered to represent statistical significance.
RESULTS
A total of 117 blood cultures were identified and considered for inclusion. Of the 117 cultures, 29 cultures were patient duplicates and 9 cultures were not available for testing and were excluded from the analysis. Hence, 79 patient bacteremic episodes were included in the analysis. Of 37 CRAB strains, 35 (95%) were bla OXA gene positive; of those 35, 32 were bla OXA-40 gene positive and 3 bla OXA-23 gene positive. PFGE analysis was also completed for the resistant strains. Fifteen strains were unique, 10 strains were possibly related, 6 strains were closely related, and 6 strains were identical by PFGE.
Demographics and clinical characteristics of patients in the CRAB and CNRAB groups are listed in Table 1 ; there were several differences of note. Patients in the CRAB group had more kidney transplants, more prior days of antibiotic therapy, a longer hospital stay prior to culture, a greater occurrence of Table 2 . In addition to a higher incidence of CRAB, the group of patients who died tended to be male and had more renal and hepatic dysfunction, more transplants, greater immunosuppression, more antibiotic therapy before A. baumannii bloodstream infection (BSI), a higher incidence of A. baumannii cultured from two or more sites, and greater number of days of stay in the hospital prior to culture and were located in the ICU more frequently at time of culture (P Ͻ 0.05 for all). There was a significant difference in data with respect to receipt of active antimicrobial therapy, favoring patients that survived (93.5% versus 74.2%, P ϭ 0.02); however, data with respect to time to active therapy did not significantly differ between groups (median, 2 days for both groups; P ϭ 0.72).
Outcomes stratified by CRAB and CNRAB group are listed in Table 3 . The primary endpoint value with respect to hospital mortality was greater in the CRAB group than in the CNRAB group as determined on the basis of univariate analysis (56.8% [n ϭ 21] versus 23.8% [n ϭ 10]; P Ͻ 0.01). Variables controlled for in the logistic regression are listed in Table 4 . Logistic regression did not identify carbapenem resistance as predictive of mortality (adjusted odds ratio [aOR], 0.73; 95% confidence interval [CI], 0.14 to 3.84). Renal dysfunction was the strongest predictor of mortality (aOR, 20.0). A. baumannii cultured from two or more sites (aOR, 5.8), ICU presence at the time of culture (aOR, 7.0), and every increase of log 10 days of antibiotics prior to culture (aOR, 4.5) were significant predictors of mortality. Active antimicrobial therapy was associated with a significant reduction in mortality (aOR, 0.06; 95% CI, 0.004 to 0.98). The multivariate analysis of active therapy stratified by antibiotic class is presented in Table 5 . Despite active therapy being a significant predictor, analyzing the entire patient sample for further stratification by type of active antibiotic was less instructive due to reduced statistical power, though we did note trends to better outcomes with beta-lactams and fluoroquinolones and worse outcomes with polymyxins and tetracyclines for patients in both the CRAB and CNRAB groups.
Median values for time to mortality between groups (11 days for the CRAB group versus 6 days for the CNRAB group; P ϭ 0.32) were not significantly different, as revealed by bivariate analysis. In the analyses of mortality over time, Kaplan-Meier survival curves stratified by carbapenem resistance diverged between the groups (log-rank test of survival; P Ͻ 0.01) (Fig.  1) . However, multivariate Cox regression analysis, controlling for patient status with respect to residency in an ICU at time of onset, active therapy, renal dysfunction, days of prior antibiotics, and detection of A. baumannii from two or more sources, found no association between time to mortality and carbapenem resistance (P ϭ 0.75) (Fig. 1) . Results of the Cox regression analysis were largely similar to those of the logistic regression model in that significant predictors of mortality were also found to be significant predictors of decreased time to mortality. Of note, active therapy was associated with a decreased hazard ratio of 0.16 (95% CI, 0.06 to 0.49; P ϭ 0.001) for time to mortality.
Median times to negative cultures were 2 days (interquartile range, 0 to 4 days) for patients in the CRAB group and 2 days (interquartile range, 1 to 3 days) for patients in the CNRAB group (P ϭ 0.32). The median length of stay postinfection for survivors was 9 days (interquartile range, 5 to 15 days); differences between the CRAB group (14 days; interquartile range, 11 to 21 days) and CNRAB group (6.5 days; interquartile range, 5 to 12 days) were statistically significantly different (P Ͻ 0.01). Data for length of stay postinfection were not normally distributed and thus were subjected to log transformation for multivariate models. Linear regression analyses of log-transformed data for length of stay postinfection were controlled for age, gender, renal dysfunction, presence of a central The results of those analyses were largely unrevealing. Due to the homogeneity of the resistance mechanism, no differences in outcomes based on the mechanism of resistance were discerned.
DISCUSSION
We found that patients with CRAB bloodstream infections have more chronic illnesses and more comorbidities. Importantly, inactive therapy was more significant than carbapenem susceptibility as a predictor of death and is potentially modifiable. Multiple studies have compared the significance of A. baumannii infection with that of other nosocomial pathogens (24) as well as comparing outcomes for various infections within the organism complex (9, 15) . We, like others, have found differences in mortality rates with respect to carbapenem resistance for A. baumannii infections when comparing data at the bivariate analysis level (i.e., with only carbapenem resistance status and mortality considered) (1, 14, 19, 30, 32) . These reports can be divided into those from studies of bacteremia (8, 14, 19, 20) and those from studies of other infection types (e.g., pneumonia) (13, 16, 26, 30, 32) . Most studies showed no differences in mortality rates (16, 20, 26, 32) , though some found that carbapenem resistance status conferred morbidity and mortality differences (1, 19, 30) .
Several reports have attempted to define predictors of mortality in patients with Acinetobacter bloodstream infections. Factors independently associated with mortality identified in previous studies include severity of illness (e.g., septic shock, underlying pneumonia, need for mechanical ventilation, intravascular devices, and acute respiratory distress syndrome), malignancy, and other patient comorbidities such as immunosuppression (1, 13, 20, 26, 30) . Receipt of active therapy in a timely fashion has also been shown to impact outcomes in patients with bacteremia (11), including that caused by A. baumannii (8, 14) . As seen with other studies (1, 19, 20, 26, 30) , we found that this effect is most likely to be confounded by patient disease status prior to infection and receipt of active therapy. We noted that differences between carbapenem-resistant and noncarbapenem-resistant isolates with respect to time to active therapy did not impact mortality significantly, though we may be constrained in our effort to detect differences here due to the homogeneity of the samples (i.e., most patients received timely therapy). Perhaps it is more instructive that we found trends suggesting that differences may exist on the basis of type of active antibiotics where patients receiving active beta-lactams (including ampicillin-sulbactam) trended toward better outcomes and those receiving polymyxins fared worse. In a retrospective study of 80 patients, Kwon et al. found that patients with imipenem-resistant Acinetobacter bacteremia suffered from significantly higher 30-day mortality than patients with imipenem-nonresistant Acinetobacter bacteremia (57.5% versus 27.5%; P ϭ 0.007) when evaluated by bivariate (14) . Subsequent multivariate analysis found, however, that imipenem resistance did not reach significance (P ϭ 0.07) as an independent risk factor for mortality. Patient age, Pitt bacteremia score, immunosuppression status, and discordant therapy were all independently associated with mortality in their cohort. The authors of that study concluded that imipenem resistance was the main driver of discordant therapy results. Removing discordant therapy from the multivariate model resulted in data for imipenem resistance reaching statistical significance (P ϭ 0.005). Given the collinearity of the variables, doubt is cast on the direct relevance of carbapenem susceptibility for outcomes. Our results suggest that active antimicrobial therapy may be a more important factor. In comparison, a retrospective, matched cohort study by Sunenshine et al. of 187 patients with infections of any site found an independent association with an increased duration of hospital and ICU stay on the multivariate level for patients infected with carbapenem-resistant A. baumannii (OR, 2.5; 95% CI, 1.2 to 5.2) versus patients with non-carbapenemresistant A. baumannii (OR, 2.1; 95% CI, 1 to 4.3) (32). However, that analysis did not control for active antibiotic therapy, which predicted a 5-fold increase in ICU length of stay. This study did not find a difference between patients in the CRAB group and patients in the CNRAB group in mortality rates (OR, 2.6; 95% CI, 0.3 to 26.1). In contrast to that study, we reviewed only bloodstream infections, which may represent a more severely ill patient population. Hence, active antibiotic therapy may have the largest impact in bacteremic patient populations.
In our study, the mortality rate for patients with CRAB bacteremia was also higher when evaluations of mortality were performed on the bivariate level (56.8% versus 23.8%; P Ͻ 0.01). When patients were stratified by mortality, many potential confounding variables, including greater patient comorbidity, emerged as possibilities for driving differences between the groups in patient demise rates. Multivariate analysis controlling for these factors revealed that carbapenem resistance was not predictive of mortality for the patients in this study. Markers of morbidity such as renal function (aOR, 20.0; P Ͻ 0.01) and the presence of a high burden of Acinetobacter as evidenced by detection of A. baumannii in cultures from two or more sites (aOR, 5.8; P ϭ 0.03) were independent predictors of mortality. Receipt of active antimicrobial therapy reduced the odds of mortality significantly (aOR, 0.06; P ϭ 0.05), although there did not appear to be a difference in mortality rates when data for patients with carbapenem resistance were adjusted for receipt of active therapy. Unlike the Kwon study, removal of active therapy from our multivariate model did not impact the significance of carbapenem resistance as a predictor of mortality (data not shown). Hence, the variables in our study do not appear colinear, and active therapy was a more important predictor of outcomes than carbapenem resistance status. This leads to the speculation that the type of active therapy a patient receives (i.e., class of antibiotics) may significantly drive outcomes for A. baumannii bloodstream infections.
In the Cox regression model, when we controlled for appropriate confounding variables, CRAB data ranged from statistically significant in the bivariate analysis to nonsignificant in the multivariate analysis. However, active therapy data remained highly statistically significant (P ϭ 0.001) even after we controlled for the appropriate confounding variables. This analysis suggests that active therapy in and of itself is more important than the presence of resistant organisms with respect to patient outcomes.
We have analyzed the carbapenem resistance mechanisms in this study and noted that they were primarily due to the presence of the bla OXA-40 gene. Due to the homogeneity of the resistance profiles in our study, we were unable to differentiate outcomes resulting from individual resistance mechanisms. Our carbapenem-resistant isolates represented a heterogenous population of A. baumannii, with only 6 strains showing identical PFGE profiles. A. baumannii is known to be a highly clonal organism with many carbapenem-resistant strains; most of the strains diverge from one of three European clonal lineages, and PFGE is slightly insensitive to detection of subtle genome changes (2, 10) . Strains belonging to a single clone causing outbreaks have been reported locally, nationally, and internationally (18, 20, 22) . Note, however, that bla OXA-40 is a gene that may be present on chromosomal DNA or acquired via plasmid carriage (12, 17) ; thus, its prevalence does not necessarily indicate that an infection was caused by a strain belonging to a single clone. PFGE analyses of isolates in this study revealed relatively broad heterogeneity. Given the tightly clonal characteristics of the organism, it is unlikely that the patients in the CRAB group were infected by a single hypervirulent strain.
Limitations to these data should be considered. This report represents a retrospective analysis with a relatively small number of patients. As noted, patients in this study had significant and often severe comorbidities. The number of differences between the patients in the CRAB group and those in the CNRAB group underscores the importance of classifying comorbidity variables. As many of the bacteremias in this study were acquired outside the ICU, we chose not to use Acute Physiology And Chronic Health Evaluation (APACHE) scores for severity of illness.
FIG. 1. Kaplan-Meier survival curves for patients stratified by carbapenem resistance. P ϭ Ͻ0.01 for log rank at the bivariate level; P ϭ 0.75 for carbapenem resistance in Cox regression analyses controlling for renal dysfunction, incidence of A. baumannii cultured from two or more sites, ICU residency at onset, active therapy, and days of antibiotics prior to culture.
This study revealed that patients infected with CRAB BSI are more chronically ill, have more comorbidities, and may receive active therapy less frequently. The presence of CRAB did not predict mortality in bacteremic patients when we appropriately controlled for confounders. Inactive therapy was a predictor of death in this study, and our results suggest that difficulties in treating CRAB infections may be due to the challenges of optimizing antimicrobial therapy in the setting of highly resistant pathogens. Larger studies may be more adequately powered to detect differences in outcomes based on carbapenem resistance, but the existing literature would indicate that infections with CRAB are more likely a marker of patients with significant morbidity. It is reassuring to speculate that novel compounds may render carbapenem-resistant A. baumannii equally treatable and that these organisms may not represent hypervirulent threats.
